01875nas a2200313   4500000000100000008004100001260001700042653001200059653002600071653003000097653001100127653002300138653001200161653001000173653000900183653001600192653001400208653000900222653001700231653001300248100001600261700001500277700001600292245014000308300001100448490000700459520108100466022001401547       2005                            d  c2005 Mar-Apr10aAnimals10aAnti-Bacterial Agents10aDrug Therapy, Combination10aKidney10aLeprostatic Agents10aleprosy10aLiver10aMale10aMinocycline10aOfloxacin10aRats10aRats, Wistar10aRifampin1 aMalfará WR1 aUyemura SA1 aQueiroz RHC00a[Correlation between dose/plasma concentration and assessment of hepatic and renal changes in Wistar rats treated with the ROM scheme].  a167-720 v383 a<p>Leprosy, a chronic granulomatous infectocontagious disease transmitted by Mycobacterium leprae, continues to be prevalent today, especially in underdeveloped countries and its paucibacillary form with a single lesion is being treated with rifampicin (600mg), ofloxacin (400mg) and minocycline (100mg) administered as a single dose (ROM scheme). Thus, the objective of the present study was to investigate the dose/plasma concentration correlation versus biochemical changes occurring in male Wistar rats receiving a single dose of rifampicin, ofloxacin and minocycline in mono- and polytherapy. Rifampicin and ofloxacin showed an increased concentration in plasma when administered in polytherapy, whereas minocycline was reduced, probably due to interference with its biotransformation and excretion. Biochemical analyses showed that rifampicin is probably responsible for hepatic and renal changes and that the medicamentous interactions involving the drug require individualized studies, especially when the drug is associated with ofloxacin and minocycline therapy.</p>  a0037-8682